DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration. 2020

Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
Department of Ultrasound, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yanjiangxi Rd., Guangzhou, 510120 Guangdong Province, China.

BACKGROUND RNA helicases have various essential functions in basically all aspects of RNA metabolism, not only unwinding RNA but also disturbing the interaction of RNA with proteins. Recently, RNA helicases have been considered potential targets in cancers. So far, there has been no detailed investigation of the biological functions of RNA helicase DHX37 in cancers. OBJECTIVE We aim to identify the prognostic value of DHX37 associated with tumor microenvironments in cancers. METHODS DHX37 expression was examined via the Oncomine database and Tumor Immune Estimation Resource (TIMER). We explored the prognostic role of DHX37 in cancers across various databases. Coexpression genes, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG), and fundamental regulators were performed via LinkedOmics. Confirming the prognostic value of DHX37 in liver hepatocellular carcinoma (LIHC) and lung adenocarcinoma (LUAD), we explored the role of DHX37 in infiltrated lymphocytes in cancers using the Gene Expression Profiling Interactive Analysis (GEPIA) and TIMER databases. RESULTS Through GO and KEGG analyses, expression of DHX37 was also correlated with complex function-specific networks involving the ribosome and RNA metabolic signaling pathways. In LIHC and LUAD, DHX37 expression showed significant positive correlations with markers of Tregs, myeloid-derived suppressor cells (MDSCs), and T cell exhaustion, contributing to immune tolerance. CONCLUSIONS These results indicate that DHX37 can serve as a prognostic biomarker in LIHC and LUAD while having an important role in immune tolerance by activating the function of Tregs, MDSC, and T cell exhaustion.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072737 Myeloid-Derived Suppressor Cells A heterogeneous, immature population of myeloid cells that can suppress the activity of T-CELLS and NATURAL KILLER CELLS in the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNE RESPONSE. They play important roles in ONCOGENESIS; INFLAMMATION; and INFECTION. MDSC,Myeloid Derived Suppressor Cell,MDSCs,Cell, Myeloid-Derived Suppressor,Cells, Myeloid-Derived Suppressor,Myeloid Derived Suppressor Cells,Myeloid-Derived Suppressor Cell,Suppressor Cell, Myeloid-Derived,Suppressor Cells, Myeloid-Derived
D000077192 Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer. Lung Adenocarcinoma,Adenocarcinoma, Lung,Adenocarcinomas, Lung,Lung Adenocarcinomas
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
June 2022, Thoracic cancer,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
January 2021, Frontiers in medicine,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
January 2024, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
August 2021, Aging,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
April 2024, Computers in biology and medicine,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
January 2022, Frontiers in genetics,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
June 2021, Scientific reports,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
January 2024, Journal of cancer research and clinical oncology,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
January 2022, Frontiers in oncology,
Yanni Xu, and Qiongchao Jiang, and Hejun Liu, and Xiaoyun Xiao, and Dinghong Yang, and Phei Er Saw, and Baoming Luo
April 2024, Combinatorial chemistry & high throughput screening,
Copied contents to your clipboard!